MOSCOW, June 1, 2016 /PRNewswire/ --
Hepatera LLC and it`s development partner MYR GmbH today announced that the results of the first-in-man Phase 1 study in healthy volunteers, and the proof-of-concept Phase 2a study in HBV/HDV co-infected patients were published as two separate “back-to-back” articles in Journal of Hepatology and are available online.
(Logo: http://photos.prnewswire.com/prnh/20140213/668442-b )
“We are pleased that the one of the most important peer-reviewed hepatology journals was interested to publish our clinical results, - said Dr. Alexander Alexandrov, Medical Director MYR GmbH. - The studies have shown a very good safety profile and strong antiviral efficacy of our drug, and can now be widely discussed in the scientific and medical community.”
“We are carefully watching the emerging developments in the HBV/HDV field and Myrcludex B is one of the intriguing new concepts”, - said Heiner Wedemeyer, co-author of Phase 2a publication and Principle Investigator of the ongoing Phase 2b clinical trial with Myrcludex B. - We hope this novel drug will contribute to the urgently needed new treatment options for the chronic HBV/HDV infection.”
About Myrcludex B
Myrcludex B is a first-in-class entry inhibitor for treatment of chronic hepatitis B and D infections. The drug inhibits the recently identified HBV receptor on the hepatocyte surface and prevents the infection of the healthy cells and viral spreading within the liver.
About Hepatera
The main activity of the company is the development of safe and effective drugs for the treatment of liver diseases for the Russian market. Myrcludex B is being developed in the framework of international cooperation with the biotechnology company MYR, GmbH (Germany).
About MYR GmbH
MYR GmbH is a clinical stage biotechnology company focused on drugs for the treatment of chronic hepatitis B and D virus infections. The company was founded in 2010 and is based in Burgwedel, Germany and is supported by investors Maxwell Biotech and High-Tech Gründerfonds (HTGF).
About Maxwell Biotech Venture Fund
Maxwell Biotech Venture Fund (MBVF) is the first Russian venture fund fully dedicated to investments in the life sciences sector. The fund has been created with the participation of the Russian Venture Company (RVC). MBVF portfolio companies have nine innovative clinical stage drug candidates in development; four thereof are in Phase 2.
Press contacts
Maxwell Biotech Group
Natalia Bakrenko
+7-(495)726-52-53
bakrenko@ammaxwell.ru
